Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 206

Similar articles for PubMed (Select 18350599)

1.

Is human hepatocellular carcinoma a hormone-responsive tumor?

Di Maio M, Daniele B, Pignata S, Gallo C, De Maio E, Morabito A, Piccirillo MC, Perrone F.

World J Gastroenterol. 2008 Mar 21;14(11):1682-9. Review.

2.

Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.

Abdel-Rahman O, Lamarca A, Valle JW, Hubner RA.

Endocr Relat Cancer. 2014;21(6):R485-93. doi: 10.1530/ERC-14-0389. Epub 2014 Oct 21. Review.

3.

Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers.

Kanda T, Jiang X, Yokosuka O.

World J Gastroenterol. 2014 Jul 28;20(28):9229-36. doi: 10.3748/wjg.v20.i28.9229. Review.

4.

Medical treatment of hepatocellular carcinoma.

Germano D, Tinessa V, Barletta E, Cannella L, Daniele B.

Minerva Med. 2013 Oct;104(5):545-61. Review.

PMID:
24101112
5.

In memoriam: Elwood Jensen (1920-2012).

Greene GL.

Endocrinology. 2013 Oct;154(10):3489-91. doi: 10.1210/en.2013-1009. No abstract available.

PMID:
24058153
6.

Progesterone and related compounds in hepatocellular carcinoma: basic and clinical aspects.

Yeh YT, Chang CW, Wei RJ, Wang SN.

Biomed Res Int. 2013;2013:290575. doi: 10.1155/2013/290575. Epub 2013 Jan 16. Review.

7.

[Change and perspective in endocrine therapy].

Yamashita H, Toyama T, Iwase H, Kobayashi S.

Nihon Rinsho. 2012 Sep;70 Suppl 7:29-34. Japanese. No abstract available.

PMID:
23350361
8.

Advanced vulvar apocrine carcinoma expressing estrogen receptors that responds to tamoxifen therapy.

Goldstein R, Stefanato CM, Warbey V, Harries M.

Future Oncol. 2012 Sep;8(9):1199-203. doi: 10.2217/fon.12.94.

PMID:
23030494
9.

Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.

Jiang T, Zhu AX, Sahani DV.

J Hepatol. 2013 Jan;58(1):169-77. doi: 10.1016/j.jhep.2012.08.022. Epub 2012 Aug 31. Review.

PMID:
22944253
10.

APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review.

Tan CH, Low SC, Thng CH.

Int J Hepatol. 2011;2011:519783. doi: 10.4061/2011/519783. Epub 2011 Apr 19.

11.

Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma.

Chow PK, Machin D, Chen Y, Zhang X, Win KM, Hoang HH, Nguyen BD, Jin MY, Lobo R, Findlay M, Lim CH, Tan SB, Gandhi M, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group.

Br J Cancer. 2011 Sep 27;105(7):945-52. doi: 10.1038/bjc.2011.333. Epub 2011 Aug 23.

12.
13.

Targeting rapid action of sex steroid receptors in breast and prostate cancers.

Giovannelli P, Di Donato M, Giraldi T, Migliaccio A, Castoria G, Auricchio F.

Front Biosci (Landmark Ed). 2011 Jun 1;16:2224-32. Review.

PMID:
21622172
14.

Sex hormones in veterinary practice.

DETWEILER DK.

Br Vet J. 1946 Feb;102:45-52. No abstract available.

PMID:
21013372
15.

Gender disparity of hepatocellular carcinoma: the roles of sex hormones.

Yeh SH, Chen PJ.

Oncology. 2010 Jul;78 Suppl 1:172-9. doi: 10.1159/000315247. Epub 2010 Jul 8.

PMID:
20616601
16.

Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials.

Jia WD, Zhang CH, Xu GL, Ge YS, Wang W.

Hepatogastroenterology. 2010 Mar-Apr;57(98):292-9. Review.

PMID:
20583430
17.

Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma.

Hua YP, Yin XY, Peng BG, Li SQ, Lai JM, Liang HZ, Liang LJ.

Chemotherapy. 2009;55(5):312-20. doi: 10.1159/000227763. Epub 2009 Jul 6.

PMID:
19590186
18.

Systemic therapies in hepatocellular carcinoma.

W├Ârns MA, Weinmann A, Schuchmann M, Galle PR.

Dig Dis. 2009;27(2):175-88. doi: 10.1159/000218351. Epub 2009 Jun 22. Review.

PMID:
19546557
19.

Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.

Higgins MJ, Stearns V.

Clin Chem. 2009 Aug;55(8):1453-5. doi: 10.1373/clinchem.2009.125377. Epub 2009 Jun 18. No abstract available.

20.

Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.

Guo TK, Hao XY, Ma B, Yang KH, Li YP, Li HL, Gu YH, Cai H, Liu YL, Li Y, Zhan WP.

J Cancer Res Clin Oncol. 2009 Dec;135(12):1685-92. doi: 10.1007/s00432-009-0615-3. Epub 2009 Jun 18.

PMID:
19536563
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk